Latest Regulatory News

Diamond Infraco 1 Pty Ltd, backed by IFM Global Infrastructure Fund, has tabled an all-cash takeover offer for the remaining Atlas Arteria securities at A$4.75, rising to A$5.10 if a 45% stake is secured. The bid comes amid concerns over Atlas Arteria’s recent strategic pivot and operational underperformance.

Brazilian Rare Earths (ASX: BRE) has reported substantial expansion of its Monte Alto rare earth project with ultra high-grade drilling results and validated low-temperature processing delivering 97% recovery. The company also secured a Trial Mining Licence enabling early production and bulk shipments.

Biome Australia has taken a significant step in its innovation journey by filing a patent for its next generation probiotic strain BMB18, with a clinical trial set to begin in Q4 FY26 in partnership with La Trobe University.

Alterity Therapeutics has secured FDA alignment on the chemistry and manufacturing controls for its ATH434 Phase 3 trial in Multiple System Atrophy, marking a pivotal regulatory milestone ahead of the planned mid-2026 End-of-Phase 2 meeting.

Sentinel Metals is poised to launch its maiden drilling campaign at the Columbia Gold-Silver Project in Montana, pending final regulatory approval. The company also bolsters its local engagement with a strategic executive hire and advances environmental studies.

Generation Development Group’s subsidiary Generation Life Limited has swiftly contained a cyber incident involving unauthorised access through a third-party provider, with no evidence of impact on core systems or unauthorised transactions.

Imricor Medical Systems updates its SEC Form 10 with minor SEC-driven revisions as it pushes forward with FDA clearances and clinical trials, reporting a $25.3 million net loss in 2025 amid early-stage commercialisation.

The FDA has removed the postmarketing cardiac repolarization study requirement for Clinuvel's SCENESSE®, reflecting confidence in its long-term safety profile. This marks a regulatory milestone for the only approved treatment for erythropoietic protoporphyria in the US.

Diatreme Resources reported a $745,000 net loss for FY 2025 but strengthened its financial footing through asset sales and an IPO stake. The company’s Northern Silica Project and Cyclone Zircon Project showed significant technical progress, while a major Cape Flattery asset sale aims to streamline operations and unlock funding.

Klevo Rewards has made major strides in Q1 2026, unveiling an Australian dollar-backed stablecoin and securing SWIFT network access through Fly Wallet, boosting its global payments and rewards platform.

Boab Metals has locked in a A$236 million syndicated loan split evenly between AUD and USD tranches to fund the Sorby Hills Silver-Lead Project, with first drawdown expected in Q3 2026 and production targeted for late 2027.

Loyal Metals Ltd has entered a binding scheme implementation deed with Indonesia’s PT Bumi Resources Tbk to sell all shares for A$0.45 each, valuing the company at approximately A$79.1 million. The transaction offers shareholders an immediate cash premium of over 40% and is supported by Loyal’s board and major shareholders.